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Introduction: Human hematopoietic stem cells (HSCs) have been clinically used for transplantation and gene and
cellular therapy for more than 4 decades. However, this use is limited because of the challenges in the ex vivo
culturing of HSCs. The major hurdle is to amplify these cells without losing their self-renewing property.
Methods: In our study, we tested 3′,4′-dimethoxyflavone (3′4′-DMF) and valproic acid (VPA) on the ex vivo
expansion of HSCs under both normoxic (20% O2) and hypoxic (1% O2) conditions. 3′4′-DMF is a widely used
anticancer drug that acts as a competitive antagonist of the aryl hydrocarbon receptor. VPA is a potent inhibitor of
histone deacetylase and is used in the treatment of neurologic disorders.
Results: Culturing HSCs (from mobilized peripheral blood) under normoxia, with 3′4′-DMF and VPA, highly
preserved the CD34 positivity (3′4′-DMF, 22.1%, VPA, 20.3%) after 1 week and strongly enhanced the CD34+ cells
(3′4′-DMF, 27.8 fold; VPA, 34.1 fold) compared with the control cultures (11.6% and 14.4 fold). Addition of 3′4′-DMF
and VPA also resulted in more primary colonies and replating efficiency compared with control cultures. Although
no significant effect was observed on the enhancement of CD34+ cells under hypoxia, the number of primary
colonies was significantly higher than the control cultures.
Conclusions: Based on these findings, this study presents, for the first time, in vitro evidence for a new and
relevant effect of 3′4′-DMF on human HSCs. In addition, the results suggest a potential clinical use of 3′4′-DMF and
VPA in HSC therapy.Introduction
Ex vivo expansion of human hematopoietic stem cells
(HSCs) is a major challenge in cell therapy. Although
advances have been made in understanding the role of
various growth factors and cytokines that leads to the
progressive maturation of various cell lineages, little is
known about the factors that govern the self-renewal and
primitive nature of HSCs. Recent attempts are focused on
the identification of growth factors and pharmacologic
agents to manipulate HSCs in vitro, with the aim to
expand HSCs ex vivo, while maintaining their primary
functional characteristics.
In our study, we tested a 3′,4′-dimethoxyflavone
(3′4′-DMF) on the ex vivo expansion of HSCs. 3′4′-DMF* Correspondence: preetkiran@gmail.com
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reproduction in any medium, provided the oris a competitive antagonist of the aryl hydrocarbon receptor
(AhR) that inhibits AhR-mediated induction of cytochrome
P450 1A1 [1]. The compound blocks transformation of the
cytosolic AhR complex and formation of nuclear AhR
complexes. 3′4′-DMF has extensively been used as an
anticancer drug in various cancers (for example, breast
cancer, leukemia, and oral cancer) [1-3]. However, nothing
is known about the potential role of this compound in the
expansion and differentiation of HSCs. The selection of
3′4′-DMF was based on the earlier studies showing
the expression of AhR in HSCs [4]. The AHR is mainly a
ligand-activated transcription factor responsible for the
induction of drug-metabolizing enzymes. In addition, it has
been suggested that AHR plays an important role in
regulating hematopoiesis, for example, in HES-1-, c-MYC-,
β-catenin-, and STAT5- dependent processes [4]. Moreover,
treatment of donor mice with the AhR agonist dioxin,
2,3,7,8-tetracholorodibenzo-p-dioxin (TCDD), leads tod. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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cells in the recipient mice [5,6]. All these findings allude to
the potential role of AHR in HSCs. Recently Boitano and
co-workers [7] demonstrated the positive effect of a purine
derivative, Stem Regenin (SR1), in the ex vivo expansion of
mobilized peripheral blood-derived CD34+ cells by 50 fold
[7]. SR1 was shown to act by antagonizing the AhR. Based
on these fascinating findings, 3′4′-DMF was selected, that
also acts by inhibiting the AhR. The effect of 3′4′-DMF on
the proliferation, survival, and differentiation of CD34+ cells
was determined both under normoxic (20% O2) and
hypoxic (1% O2) conditions.
Another pharmacologic agent used in the present
study was valproic acid (VPA). Histone deacetylase
(HDAC) inhibitors (for example, VPA) have been
successfully used for more than 2 decades, for the
treatment of neurodegenerative disorders. VPA has
been used as a first-line treatment drug for bipolar
disorders. VPA helps in protecting against apoptosis
insults both in vitro and in vivo [8]. Pretreatment
with VPA protects cultured brain neurons from
glutamate-induced apoptosis [9]. It has also been
shown to display beneficial effects in cellular and
animal models of neurodegenerative diseases such as
stroke, Alzheimer disease, Parkinson disease, and
spinal cord injury [10].
Although the role of HDAC inhibitors in regulating
the growth, differentiation, and apoptosis in various
tumors has been documented very well, just a handful of
reports are available suggesting their potential use in
stem cell biology. Moreover, these studies reported the
effect of VPA on HSCs only under normoxic (20% O2)
conditions. Culturing under hypoxic conditions was
chosen because HSCs reside in specialized hypoxic niches
in the bone marrow (BM). Besides, an extensive number of
studies in the literature have shown that hypoxic ex vivo
culture of BM or primitive hematopoietic progenitors
results in the maintenance of the primitive phenotype and
cell-cycle quiescence [11,12]. In addition, culturing of
HSCs under low oxygen tension enhances the proliferation
of HSCs and maintenance of SCID-repopulating cells more
than under normoxic conditions [13].
Materials and methods
Cell source
The study protocol adhered to the guidelines of the
Declaration of Helsinki and was approved by The
Regional Committees for Medical and Health Research
Ethics (Reference number 2010/510). Mobilized peripheral
blood was collected from healthy donors, after informed
consent, at the Department of Cellular Therapy, Oslo
University Hospital. CD34+ cells were isolated from
leukophoresis blood by using CD34 magnetic micro beads
(Miltenyi Biotec, Germany) and MACS separationcolumn. Isolated cells were tested for purity by using flow
cytometry. For all isolations, the purity of CD34+ cells was
90% to 95%. The CD34+ cells were frozen in medium with
10% dimethyl sulfoxide (DMSO) and maintained in the
vapor phase of liquid nitrogen (−180°C) until use.
Phenotypic characterization of isolated CD34+ cells with
flow cytometry
The total number and the percentage of viable cells
were counted by Nucleocounter Chemometec (Allerød,
Denmark) according to manufacturer’s manual. Three-color
flow cytometry was performed to study the expression of
cell-surface antigens (CD34, CD38, CD90, CD19, CD7,
CD15, CD71, CD33, CD61) of CD34+ cells on days 0 and 7.
All monoclonal antibodies and the cell-viability
marker, 7-AAD, were obtained from BD Pharmingen
(San Jose, CA, USA). Anti-CD38-PC5 was purchased from
Beckman Coulter (Beckman Coulter, Miami, FL, USA).
Ex vivo expansion of CD34+ cells
CD34+ cells (15 × 103 cells/ml) were cultured in 12-well
flat-bottomed culture plates. The cells were cultured
in Cell Gro medium (Cell Genix, Freiburg, Germany)
supplemented with a cocktail of five cytokines:
Thrombopoietin (100 ng/ml; Cell Genix), Stem cell
factor (100 ng/ml, Cell Genix), Flt3L (100 ng/ml; Cell
Genix), interleukin 3 (20 ng/ml, Cell Genix), and
interleukin 6 (20 ng/ml, Cell Genix). 3′,4′-Dimethoxy
flavone (2.5 μM, Sigma-Aldrich, St. Louis, MO, USA)
and valproic acid (0.065 mM, Sigma-Aldrich) were
added to the tested cultures along with cytokines. The
normoxic cultures were incubated at 37°C and 5% CO2 for
7 days. The hypoxic cultures were maintained at 37°C and
1% O2 for 7 days. The cultures were supplemented
with fresh cytokines at day 4. The total number of
nucleated cells, viability, and phenotypic profiling
were evaluated at day 7.
Cell-cycle analysis
For cell-cycle analysis with flow cytometry, 1 × 105 cells
were harvested and washed with PBS, resuspended, and
fixed by slow addition of 1 ml 100% ice-cold methanol
to the mixer and stored at −20°C until analysis. After
fixation, the cells were pelleted, washed with cold PBS,
and then stained with 1.5 μg/ml Hoechst 33258 for 1
hour at 25°C in the dark. Ten thousand cells were analyzed
with flow cytometry.
Colonogenic assay
CD34+ cells were plated in Methocult (Stem Cell
Technologies, Vancouver, BC, Canada), supplemented
with IMDM (Stem Cell Technologies) and 10% FBS
(Stem Cell Technologies). 3′4′-DMF and VPA were
added to the Methocult before mixing it with the cell
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in 1 ml of prepared mixture were plated in a 35-mm
dish in triplicate and cultured for 14 days at 37°C.
The colonogenic assay was performed under normoxic
(20% O2) conditions. Because culturing under hypoxia
results in cell-cycle arrest, the colonogenic assay was
performed under normoxic conditions only.
Colonies were counted under the phase-contrast
microscope and scored into three categories: pure erythroid
(burst-forming unit (BFU-E)), myelomonocytic (granulo-
cyte-macrophage colony-forming unit (CFU-GM)), and
mixed colony-forming unit (CFU-GEMM- granulocyte,
erythroid, macrophage, megakaryocyte).
Replating efficiency
The replating efficiency of the primary colonies was
evaluated as described by De Felice et al. [14]. In brief, the
primary colonies (erythroid, granulocyte-macrophage, and
mixed colonies) were picked up individually from the
35-mm petri plate after 14 days of incubation. Each
individual colony was dispersed into single-cell suspension
in 200 μl of methylcellulose medium (Methocult) and
seeded in separate wells of a 96-well plate. The replating
efficiency was calculated as a percentage of colonies
formed by seeded cells after 14 days of incubation under
normoxia.
Statistical methods
Data are presented as mean ± SD. The Student t test was
used for significance testing. Differences were considered
significant at P < 0.05.
Results
Effect of 3′4′-DMF and VPA on the ex vivo expansion of
CD34+ cells under normoxia (20% O2)
The effect of 3′4′-DMF and VPA on the cytokine-induced
ex vivo amplification of CD34+ cells was determined
after 7 days of culture (Figure 1). Phenotypic analysis
showed a significant increase in the total number as well
as percentage of CD34+ cells in the cultures treated with
3′4′-DMF + cytokines (435,626.7 ± 69,577; 22.1% ± 2.7;
P < 0.007) and VPA + cytokines (475,980 ± 73,927;
20.3% ± 2.2; P = 0.012) compared with the control
cultures treated with cytokines alone (203,246.7 ± 39,222;
11.6% ± 1.4).
However, the percentages of CD34+CD90+ cells
(3′4′-DMF + cytokines = 0.6% ± 0.16, VPA + cytokines =
0.7% ± 0.22, control at day 7 = 0.6% ± 0.08 and con-
trol at day 0 = 0.7% ± 0.2) and CD34+ CD38- cells
(3′4′-DMF + cytokines = 1.4% ± 0.16, VPA + cytokines =
1.5% ± 0.26, control at day 7 = 1.4% ± 0.16 and control at
day 0 = 1.6% ± 0.2) did not differ between cultures
treated with 3′4′-DMF or VPA in comparison with
the control cultures.Next we evaluated expansion of CD34+ cells by dividing
the total number of cells obtained at day 7 to the
total number of cells at day 0. As shown in Figure 2,
no significant difference (P > 0.05) was found in the
proliferation of total nucleated cells (TNCs) cells in
the cultures treated with 3′4′-DMF + cytokines (121 fold)
and VPA + cytokines (158 fold), compared with the
control cultures (117 fold), treated with cytokines alone.
The viability of cells was similar in all culture conditions:
98%, 96%, and 97% for the control cultures, 3′4′-DMF +
cytokines and VPA + cytokines, respectively.
Similar to the higher percentage of CD34+ cells in
3′4′-DMF and VPA cultures, the fold difference in
the CD34+ cells was also significantly higher in the 3′
4′-DMF + cytokines (27.8 ± 3.4 fold; P = 0.03) and
VPA + cytokines (34.1 ± 4.1 fold; P = 0.004) cultures com-
pared with the cultures with cytokines alone (14.4 ± 2.9
fold). This indicates that both 3′4′-DMF and VPA
induced a significantly higher amplification of the CD34+
population under normoxia (Figure 2).
Besides the higher proliferation of CD34+ cells, cultures
with both 3′4′-DMF and VPA resulted in significantly
more (P < 0.05) primary colonies (plating efficiency) com-
pared with control cultures (Figure 3). In addition, the
replating efficiency of the cells treated with 3′4′-DMF
(49.5 ± 6.4) or VPA (54 ± 8.5) was higher than that of the
control (14.5 ± 6.4) cultures. These assays confirmed that
treatment with 3′4′-DMF and VPA helped in preserving
the plating efficiency of HSC progenitors.
Based on the promising results, we went ahead to
determine the combined effect of 3′4′-DMF and VPA on
HSCs. However, no significant difference was observed, in
the proliferation or plating efficiency, between the cultures
treated with either 3′4′-DMF or VPA and cultures treated
with both 3′4′-DMF and VPA, indicating no synergistic
effect of the two reagents on HSCs (data not shown).
Effect of 3′4′-DMF and VPA on the ex vivo expansion of
CD34+ cells under hypoxia (1% O2)
In a similar way, the CD34+ cells were cultured under
hypoxia (1% O2) to determine the effect of 3′4′-DMF
and VPA on their proliferation and maintaining of
CD34 expression. In contrast to the normoxic cultures, a
higher expression of CD34 was found in cultures under
hypoxia (73% ± 2.4) after 7 days, suggesting that hypoxia
plays a role in maintaining the primitive nature of the cells
(Figure 4). However, neither 3′4′-DMF (76% ± 2.7) nor
VPA (77% ± 1.9) increased the expansion of CD34+ cells
compared with control (73% ± 2.4) cultures under
hypoxia (Figure 4). The percentages of CD34+CD90+ cells
(3′4′-DMF + cytokines = 0.7% ± 0.2, VPA + cytokines =
0.6% ± 0.12, control at day 7 = 0.6% ± 0.17%, and control
at day 0 = 0.7% ± 0.2) and CD34+CD38- cells (3′4′-
DMF + cytokines = 1.5% ± 0.2; VPA + cytokines =
Figure 1 3′4′-Dimethoxyflavone (DMF) and valproic acid (VPA) enhance the proportion of CD34+ cells. The mean number and percentage
of CD34+ cells was evaluated before (day 0) and after (day 7) the initiation of cytokine-induced cultures. (A) More mean CD34+ cells were found
in the cultures with 3′4′-DMF and VPA compared with the control cultures after 7 days of amplification. (B): A higher percentage was found in
the cultures with 3′4′-DMF and VPA compared with the control cultures after 7 days of amplification. (C) FACS analysis plots of CD34+ fractions
from representative samples before (day 0) and after 7 days of amplification with cytokines alone (control), with 3′4′-DMF + cytokines and with
VPA + cytokines. 3′4′-DMF ( ), VPA ( ), control at day 0( ) and control at day 7 ( ). The columns represent the mean ± SD values from
three independent experiments.
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day 0 = 1.6% ± 0.2) did not show any difference in the cul-
tures treated with 3′4′-DMF or VPA in comparison with
the control cultures.
Next we investigated the effect of 3′4′-DMF and VPA
on the fold increase of TNC and CD34+ cells under
hypoxia. After 7 days of culture, no difference was
observed in the total number of nucleated cells in the
control cultures (11.7 ± 0.45 fold) with cytokines alone
compared with 3′4′-DMF + cytokines (10.7 ± 0.25 fold)
and VPA + cytokines (13 ± 1.1 fold) cultures (Figure 5).
The TNC count suggested cell-cycle arrest, which was con-
firmed by cell-cycle analysis. The cell-cycle analysis revealed
an increased number of cells in G0 + G1 phase (cytokines
alone = 67% ± 1.2; 3′4′-DMF + cytokines = 68% ± 2.0;
and VPA + cytokines = 67% ± 1.5) and decreased
number of cells in S phase (cytokines alone = 26% ± 1.1,3′4′-DMF + cytokines = 27% ± 1.0; and VPA + cytokines
= 27% ± 0.8) for all three culture conditions under hyp-
oxia, when compared with the cells cultured under
normoxia (G0 + G1 phase: cytokines alone = 59.5% ±
1.2; 3′4′-DMF + cytokines = 56.4% ± 1.3; and VPA +
cytokines = 57% ± 1.6. S phase: cytokines alone =
32.5% ± 0.9%, 3′4′-DMF + cytokines = 35% ± 1.1;
and VPA + cytokines = 35% ± 1.3). In addition, 3′4′-DMF
(4.7 ± 0.29 fold) and VPA (5.5 ± 0.37 fold) had no signifi-
cant effect on the fold increase of CD34+ cells in compari-
son to the control (4.5 ± 0.34 fold) cultures (Figure 5).
Further, we determined the effect of 3′4′-DMF and
VPA on the colony-formation assay of HSCs cultured
under hypoxia. The HSCs were cultured under hypoxia
for 7 days, followed by the CFU assay performed under
normoxia. After 14 days, the primary colonies (BFU,
CFU-GM, and mixed colonies) were counted. Except for
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primary colonies (total CFU, CFU-GM, and mixed CFU)
in cultures treated with both 3′4′-DMF and VPA compared
with the control cultures (Figure 6).
Similar to normoxia, no synergistic effect of 3′4′-DMF
and VPA was observed on HSCs under hypoxia (data
not shown).
Discussion
In this study, we investigated the effect of 3′4′-DMF and
VPA on ex vivo expansion of HSCs under normoxia and
hypoxia. Although the beneficial effects of VPA have
been suggested before [11,12], our report is the first,
to the best of our knowledge, to show an effect of
3′4′-DMF on HSCs.
Recently, Boitano and co-workers [7] reported the
beneficial effects of a purine derivative, SR1, on the
expansion of human CD34+ cells, from mobilized
peripheral blood of donors, by antagonizing the AHR.
Although 3′4-DMF has also an effect similar to that of
SR1, it has not been previously used in ex vivo culturing
of HSCs. Treatment of HSC cultures with 3′4′-DMF
similarly enhanced the ex vivo generation of CD34+ cells
(27.6 fold compared with 14.5 fold in control) under
normoxia (20% O2). Thus, our finding is in agreement
with Boitano et al. [7], who demonstrated expansion of
HSCs with another AhR antagonist, SR1.
Contrary to the results obtained under normoxia, no
effect on the expansion of CD34+ cells was observed in
the cultures stimulated with 3′4′-DMF under hypoxia
(1% O2). However, plating efficiency was higher in the
3′4′-DMF cultures compared with control, underFigure 2 3′4′-Dimethoxyflavone (DMF) and valproic acid (VPA)
increased the proliferation of CD34+ cells in 7-day culture. The
effect of 3′4′-DMF and VPA on the amplification of TNC and CD34+
cells was evaluated as fold increase over the input (day 0) values.
3′4′-DMF ( ), VPA ( ), control ( ). The columns represent the
mean ± SD values from three independent experiments.normoxia and hypoxia. This indicates that 3′4′-DMF
helps to preserve the hematopoietic progenitors under
both normoxia and hypoxia.
The mechanistic studies have shown that 3′4′-DMF
acts by directly binding to the AHR, and in turn inhibits
the AHR-mediated induction of cytochrome P450 1A1
(CYP1A1) and cytochrome P450 1B1 (CYP1B1). However,
the mechanisms of this inhibitory effect of 3′4′-DMF on
the expression of these enzymes (CYP1A1 and CYP1B1)
remain to be elucidated. The expression of the AHR in
HSCs suggests that similar mechanisms (inhibition of
AHR-mediated induction of CYP1B1 and CYP1A1) could
play a role in the expansion and maintenance of HSCs
[14]. However, further studies are required to define the
role of CYP1A1 and CYP1B1 as well as the molecular
mechanisms involved in these processes. Nevertheless,
our data suggest the potential use of a 3′4′-DMF in HSC
expansion and maintenance, which requires validation by
further studies. Besides, in vivo studies, using NOD SCID
Gamma (NSG) mouse model, would provide strong
supporting evidence to our findings, which, unfortunately,
could not be accomplished in the present study because of
lack of resources.
The present study has also demonstrated the positive
effect of VPA on ex vivo expansion of HSCs. Although the
potential use of VPA, in the expansion of HSCs, has been
documented before [15-18], findings of the present study
were different from earlier reports, in terms of percentage
of CD34+ cells, cell cycle, and CFU. Moreover, nothing is
known about the use of VPA on the proliferation, differen-
tiation, survival, and maintenance of the primitive nature of
human HSCs under hypoxia. In addition, reported studies
used a higher concentration of VPA (1 mM) in the cultures
[15-18]. The concentration of VPA (0.065 mM) used in ourFigure 3 More committed progenitors (BFU-E, CFU-GM, and
CFU-GEMM) in the cultures treated with 3′4′-dimethoxyflavone
(DMF) or valproic acid (VPA) compared with the control
cultures. 3′4′-DMF ( ), VPA ( ), control ( ). The columns
represent the mean ± SD values from three independent experiments.
Figure 5 The effect of 3′4′-dimethoxyflavone (DMF) and
valproic acid (VPA) on the amplification of TNC and CD34+ cells,
after 7 days of culture under hypoxia, was evaluated as fold
increase over the input (day = 0) values. 3′4′-DMF ( ), VPA ( ),
control D, 0 ( ). The columns represent the mean ± SD values
from three independent experiments.
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tions used by Felice et al. (1 mM) [14], Bug et al. (0.9 mM)
[16], and Burba et al. (2.5 mM) [18], and in addition, we
also tested the effect of VPA under hypoxic conditions. All
these studies reported an expansion of CD34+ in human
HSC cultures after 7 days. On the contrary, in the present
study, the percentage of CD34+ cells decreased after 7 days
of culture compared with input cells at day 0. However, the
percentage of CD34+ cells (20.3%) in our study was com-
parable to the results obtained by Seet et al. [17], which
could again be attributed to the higher concentrations of
VPA used in other studies [15,16,18].
The present study showed that exposure to VPA
enhances the number of CFUs in HSCs, in contrast to
the results obtained by De Felice et al. [15], in which the
number of CFUs decreased in the cultures stimulated
with VPA. Moreover, contrary to De Felice et al., in
which authors showed that VPA lengthens the duration
of cell cycle, with most of the cells in G0/G1 phase [15],
we did not observe any cell-cycle arrest.
Notably, our data showed a 19.5-fold increase in CD34+
cells after 7 days in VPA cultures compared with control
cultures (34 fold versus 14.5 fold), which was inFigure 4 Effect of 3′4′-dimethoxyflavone (DMF) and valproic
acid (VPA) on the frequency of CD34+ cells in the cultures
under hypoxia (1% O2). The percentage of CD34
+ cells was
evaluated before (day 0) and after (day 7) the amplification of
cytokine-induced cultures of CD34+ cells, maintained at low O2 (1%)
tension. 3′4′-DMF ( ),VPA ( ), control D = 0 ( ), control D7 ( ).
The columns represent the mean ± SD values from three
independent experiments.agreement with the study by De Felice et al. [15].
Moreover, both the studies demonstrated an increase
in the replating efficiency of the cells in VPA + cytokines
cultures compared with the control cultures.
Surprisingly, our data is in agreement with the results
obtained by Bug et al., [16] in terms of CFU and
cell-cycle analysis. In this study, authors exposed theFigure 6 Effect of 3′4′-dimethoxyflavone (DMF) and valproic
acid (VPA) on the committed progenitors of HSCs after 7 days
of culture under hypoxia. A significantly higher number of total
colonies and colonies of committed progenitors (CFU-GM and CFU-
GEMM) in the cultures treated with 3′4′-DMF or VPA compared with
the control cultures. Columns, mean; bars, ±SD. 3′4′-DMF ( ), VPA
( ), control ( ). The columns represent the mean ± SD values
from three independent experiments.
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increased the number of CFUs and the replating efficiency.
Also in contrast to the control, VPA-treated cultures had
increased percentages of cells in the S phase. These results
suggest that exposure of human HSCs to low concentra-
tion of VPA could have an effect similar to that of the
treatment of murine HSCs with high VPA concentrations,
which points toward the potential possibility of different
biochemical pathways or different signaling molecules
involved in the two species.
In contrast to the normoxic cultures, VPA did not
stimulate the enhancement of proliferation of TNC or
CD34+ cells under hypoxia. However, VPA significantly
increased the plating efficiency of HSCs compared with
control untreated cultures. Hence, as in 3′4′-DMF, VPA
could play a role in preserving the progenitors, under
both normoxia and hypoxia.
Conclusions
In conclusion, our study suggests a positive effect of
3′4′-DMF on human hematopoietic stem cells. However,
it warrants further studies to validate our findings as well as
to explore further the potential benefits of 3′4′-DMF, either
alone or in synergy with other agents, in HSC biology.
Further studies are required to clarify the use of VPA,
especially with same cell source, similar culture conditions,
and cytokine cocktail, to find an optimal VPA concentra-
tion for ex vivo expansion and maintenance of human
HSCs. Moreover, the differences in mouse and human
HSCs, when exposed to VPA, should be investigated fur-
ther before using the former as in vivo model for the study.
Abbreviations
3′4′-DMF: 3′4′-dimethoxyflavone; CFU: Colony-forming unit;
HSC: Hematopoietic stem cell; VPA: Valproic acid.
Competing interests
None of the authors of this manuscript has any relevant conflicts/interests to
declare.
Authors’ contributions
KK helped in designing the study, designed the experiments, carried out the
cell-culture experiments and colonogenic experiments, performed statistical
analysis, and drafted the manuscript. MRM helped in designing the
experiments, isolated CD34+ cells, carried out the FACS and cell-cycle
experiments, and contributed in the discussion and interpretation of results.
GK provided CD34+ cells and contributed in the discussion and
interpretation of results. JKK conceived the study and helped in the design
and coordination of the study and interpretation of results. All the authors
read and approved the final manuscript.
Authors’ information
KK is a PhD in molecular genetics and worked for 1 year on this project as a
postdoctoral researcher at Department of Immunology and Transfusion
Medicine, Oslo University Hospital, Oslo, Norway. MRM is a PhD and works as
a researcher at Department of Cellular Therapy, Oslo University Hospital,
Ullevål, Oslo, Norway.
GK is a PhD, working as Head of the Department of Cellular Therapy, Oslo
University Hospital, Radiumhospitalet, Oslo, Norway.
JKK has had a position as Senior Consultant Physician (since 1996) and
Professor of Transfusion Medicine (since 2004). His presents address isDepartment of Clinical Immunology and Transfusion Medicine, University
and Regional Laboratories Region Skåne, Lund, Sweden.Acknowledgements
The authors thank the stem cell donors. The study was supported by the
European Union’s 7th Framework Programme (grant number 222741,
METOXIA) and by a grant from the South-Eastern Norway Regional Health
Authority (project number 2006240).
Author details
1Department of Immunology and Transfusion Medicine, Oslo University
Hospital, Ullevål, Oslo, Norway. 2Department of Cellular Therapy, Oslo
University Hospital, Radiumhospitalet, Oslo, Norway.
Received: 23 November 2012 Revised: 4 April 2013
Accepted: 14 May 2013 Published: 24 May 2013References
1. Lee JE, Safe S: 3′,4′-Dimethoxyflavone as an aryl hydrocarbon receptor
antagonist in human breast cancer cells. Toxicol Sci 2000, 58:235–242.
2. Torres F, Quintana J, Estévez F: 5,7,3'-Trihydroxy-3,4'-dimethoxyflavone-
induced cell death in human leukemia cells is dependent on caspases
and activates the MAPK pathway. Mol Carcinog 2010, 49:464–475.
3. Wen X, Walle T: Preferential induction of CYP1B1 by benzo[a]pyrene in
human oral epithelial cells: impact on DNA adduct formation and
prevention by polyphenols. Carcinogenesis 2005, 26:1774–1781.
4. Singh KP, Casado FL, Opanashuk LA, Gasiewicz TA: The aryl hydrocarbon
receptor has a normal function in the regulation of hematopoietic and other
stem/progenitor cell populations. Biochem Pharmacol 2009, 77:577–587.
5. Singh KP, Wyman A, Casado FL, Garrett RW, Gasiewicz TA: Treatment of
mice with the Ah receptor agonist and human carcinogen dioxin results
in altered numbers and function of hematopoietic stem cells.
Carcinogenesis 2009, 30:11–19.
6. Sakai R, Kajiume T, Inoue H, Kanno R, Miyazaki M, Ninomiya Y, Kanno M:
TCDD treatment eliminates the long-term reconstitution activity of
hematopoietic stem cells. Toxicol Sci 2003, 72:84–91.
7. Boitano AE, Wang J, Romeo R, Bouchez LC, Parker AE, Sutton SE, Walker JR,
Flaveny CA, Perdew GH, Denison MS, Schultz PG, Cooke MP: Aryl
hydrocarbon receptor antagonists promote the expansion of human
hematopoietic stem cells. Science 2010, 329:1345–1348.
8. Chuang DM: Neuroprotective and neurotrophic actions of the mood
stabilizer lithium: can it be used to treat neurodegenerative diseases?
Crit Rev Neurobiol 2004, 16:83–90.
9. Leng Y, Chuang DM: Endogenous alpha-synuclein is induced by valproic
acid through histone deacetylase inhibition and participates in
neuroprotection against glutamate-induced excitotoxicity. J Neurosci
2006, 26:7502–7512.
10. Tariot PN, Loy R, Ryan JM, Porsteinsson A, Ismail S: Mood stabilizers in
Alzheimer’s disease: symptomatic and neuroprotective rationales.
Adv Drug Deliv Rev 2002, 54:1567–1577.
11. Mohyeldin A, Garzón-Muvdi T, Quiñones-Hinojosa A: Oxygen in stem cell
biology: a critical component of the stem cell niche. Cell Stem Cell 2010,
7:150–161.
12. Suda T, Takubo K, Semenza GL: Metabolic regulation of hematopoietic
stem cells in the hypoxic niche. Cell Stem Cell 2011, 9:298–310.
13. Eliasson P, Rehn M, Hammar P, Larsson P, Sirenko O, Flippin LA, Cammenga
J, Jönsson JI: Hypoxia mediates low cell-cycle activity and increases the
proportion of long-term-reconstituting hematopoietic stem cells during
in vitro culture. Exp Hematol 2010, 38:301–310.
14. Frericks M, Meissner M, Esser C: Microarray analysis of the AHR system:
tissue-specific flexibility in signal and target genes. Toxicol Appl
Pharmacol 2007, 220:320–332.
15. De Felice L, Tatarelli C, Mascolo MG, Gregorj C, Agostini F, Fiorini R, Gelmetti
V, Pascale S, Padula F, Petrucci MT, Arcese W, Nervi C: Histone deacetylase
inhibitor valproic acid enhances the cytokine-induced expansion of
human hematopoietic stem cells. Cancer Res 2005, 65:1505–1513.
16. Bug G, Gül H, Schwarz K, Pfeifer H, Kampfmann M, Zheng X, Beissert T,
Boehrer S, Hoelzer D, Ottmann OG, Ruthardt M: Valproic acid stimulates
proliferation and self-renewal of hematopoietic stem cells. Cancer Res
2005, 65:2537–2541.
Kaur et al. Stem Cell Research & Therapy 2013, 4:60 Page 8 of 8
http://stemcellres.com/content/4/3/6017. Seet LF, Teng E, Lai YS, Laning J, Kraus M, Wnendt S, Merchav S, Chan SL:
Valproic acid enhances the engraftability of human umbilical cord blood
hematopoietic stem cells expanded under serum-free conditions. Eur J
Haematol 2009, 82:124–132.
18. Burba I, Colombo GI, Staszewsky LI, De Simone M, Devanna P, Nanni S,
Avitabile D, Molla F, Cosentino S, Russo I, De Angelis N, Soldo A, Biondi A,
Gambini E, Gaetano C, Farsetti A, Pompilio G, Latini R, Capogrossi MC, Pesce
M: Histone deacetylase inhibition enhances self-renewal and
cardioprotection by human cord blood-derived CD34 cells. PLoS One
2011, 6:e22158.
doi:10.1186/scrt208
Cite this article as: Kaur et al.: 3′,4′-Dimethoxyflavone and valproic acid
promotes the proliferation of human hematopoietic stem cells. Stem Cell
Research & Therapy 2013 4:60.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
